Meeting
2017 Genitourinary Cancers Symposium
CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).
Authors
Simon Pacey
University of Cambridge, Cambridge, United Kingdom
Simon Pacey , Javier Garcia Corbacho , Nimish Shah , Ola Bratt , Anne Warren , Richard D. Baird , Vincent Gnanapragasam , Sara Stearn , Susan Ingle , Leanne K Bell , William Dott , Wendi Qian , Wanfeng Zhao , Barry Davies , Elizabeth A. Harrington , Elisabeth Maria Oelmann , Mirela Hategan , Sanjeev Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT02064608
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 97)
DOI
10.1200/JCO.2017.35.6_suppl.97
Abstract #
97
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).
First Author: Simon Pacey
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.
First Author: William Gesztes
Poster
2023 ASCO Genitourinary Cancers Symposium
Planned interim analysis of perioperative safety of fluzoparib combined with abiraterone in the neoadjuvant treatment of locoregional high-risk prostate cancer: Results from multicenter, phase 2 FAST-PC trial.
First Author: Yao Zhu
Poster
2019 Genitourinary Cancers Symposium
A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) ± degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.
First Author: Simon Pacey